An investigation on behalf of investors of NxStage Medical, Inc. (NASDAQ:NXTM) in connection with the proposed takeover was announced and NASDAQ:NXTM stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 08/15/2017 -- An investigation was announced for investors, who currently hold NASDAQ:NXTM shares, concerning whether the takeover of NxStage Medical, Inc. by Fresenius Medical Care for $30.00 per share is unfair to NASDAQ:NXTM stockholders.
Investors who purchased shares of NxStage Medical, Inc. (NASDAQ:NXTM) and currently hold any of those NASDAQ:NXTM shares have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call 858-779-1554.
The investigation by a law firm concerns whether certain directors of NxStage Medical, Inc. breached their fiduciary duties owed to NASDAQ:NXTM investors in connection with the proposed acquisition.
On August 7, 2017, Fresenius Medical Care has signed an agreement to acquire NxStage Medical, Inc. (NASDAQ:NXTM). Under the terms of the proposed transaction, Fresenius Medical Care would acquire NxStage in a transaction valued at approximately $2 billion or $30.00 in cash per share.
However, given that at least one analyst set a price target NASDAQ:NXTM stock at $33.00 per share, the investigation concerns whether the offer is unfair to NASDAQ:NXTM stockholders. More specifically, the investigation concerns whether the NxStage Medical Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
On August 14, 2017, NxStage Medical, Inc. (NASDAQ:NXTM) shares closed at $29.20 per share.
Those who are current investors in NxStage Medical, Inc. shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels